Rising metabolic dysfunction drives insulin resistance treatment growth

26.5% of global population had insulin resistance in 2025.

The global insulin resistance treatment market is expected to expand steadily by 2036, with the United States leading in market size compared to the EU4 (Germany, Italy, France, Spain), the UK, and Japan, according to DelveInsight's analysis. 

Worldwide, 26.53% of the population had insulin resistance in 2025, highlighting the condition’s widespread impact.

Rising cases are driven by earlier onset of metabolic dysfunction, increased cardiometabolic conditions, lifestyle and socioeconomic factors, longer survival of chronic patients, and broader use of laboratory tests detecting subclinical insulin resistance.

New treatments are reshaping the market. GLP-1 receptor agonists and SGLT2 inhibitors are increasingly used to improve insulin sensitivity and manage weight.

The market is also set to change with upcoming therapies, including TLC-3595 (OrsoBio), Retatrutide (Eli Lilly), PATAS (AdipoPharma), and Maridebart cafraglutide (Amgen).